AZNAstraZenecaSigning up patients
Torvutatug Samrotecan Plus Bevacizumab as First-line Maintenance in Non-Homologous Recombination Deficiency (Non-HRD) Positive Advanced Epithelial Ovarian Cancer
Epithelial Ovarian Cancer
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 950 (planned)
- Started
- Sep 16, 2026
- Main results expected
- Jun 28, 2030
- Fully finished
- Aug 29, 2033
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Progression Free Survival (PFS)
Measured over: up to approximately 5 years
Changes Tremor has spotted
Moved the final finish date slightly later: Aug 17, 2033 → Aug 29, 2033.
Spotted
Moved the main results date slightly later: Jun 18, 2030 → Jun 28, 2030.
Spotted
Show details (technical version)
Score inputs
- none
Raw record changes
- 2026-11-06 15:29 UTC · date_small_change · completion_date
old: "2033-08-17"
new: "2033-08-29"
details: {"months":0.4} - 2026-11-06 15:29 UTC · date_small_change · primary_completion_date
old: "2030-06-18"
new: "2030-06-28"
details: {"months":0.3}
Trial ID NCT07851025 · record last updated 2026-11-06 · checked 2026-11-09 15:36 UTC